Linked Life Data

7086771

Source:http://linkedlifedata.com/resource/pubmed/id/7086771

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1982-8-14
pubmed:abstractText
Thirty-three patients with JRA were treated with proquazone during a 4-wk open-labeled, non-controlled trial. Increasing doses started at 400 mg/m2/d up to 800 mg/m2/d, not to exceed 960 mg/d. Oral administration was 4 times/d. One patient did not complete the study because an erythematous rash developed. Efficacy analysis showed significant decreases in the total number of active joints, the number and severity of joints with tenderness and LOM, DMS, and travel time (in all cases p less than .05). The drug appears to be similar in efficacy and safety to other NSAID that have been studied in children.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0315-162X
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
135-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:articleTitle
Proquazone (Biarsan) in the treatment of juvenile rheumatoid arthritis. A segment I study.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.